Milestone payment from Sanofi to Schrödinger for providing molecular simulation, computational design expertise

Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate.

NEW YORK: Schrödinger recently announced receipt of a preclinical milestone payment from Sanofi in a drug discovery program advancing as part of a multi-year, multi-target collaboration between the two companies.

Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate. Earlier this spring, Schrödinger announced the advancement of a separate program in autoimmune disease into clinical trials.

“This is an especially exciting moment in our collaboration with Sanofi as it marks another program advanced,” said Karen Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist.

“Achieving this milestone is a testament to the value of our ongoing collaboration with partners and our ability to efficiently identify promising therapeutic compounds," Karen added.

"The work with Sanofi is one of several collaborations Schrödinger has established with leading biotech and pharmaceutical companies around the world. These collaborations leverage Schrödinger’s physics-based computational platform to enable rapid iterations of design and analysis of potential therapeutic compounds," reads Schrodinger release.

"Such collaborations have already led to several clinical-stage assets and two FDA-approved oncology drugs. More than two dozen additional programs are moving through discovery and development in indications including oncology, diabetes, metabolic disorders, schizophrenia, and neurodegenerative diseases.," the release added.

Also Read: Sanofi gets European nod for Libtayo to treat cutaneous squamous cell carcinoma